<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04430530</url>
  </required_header>
  <id_info>
    <org_study_id>GIMI-IRB-20008</org_study_id>
    <nct_id>NCT04430530</nct_id>
  </id_info>
  <brief_title>4SCAR-T Therapy Post CD19-targeted Immunotherapy</brief_title>
  <official_title>4SCAR-T Therapy After Anti-CD19 Immunotherapy Targeting B Cell Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Geno-Immune Medical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ShiJiaZhuang Zhongxi Children Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Seventh Affilliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Geno-Immune Medical Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate safety and efficacy of a combination of 4th generation chimeric
      antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express
      alternative surface antigens such as CD22, CD10, CD20, CD38, and CD123, as many patients
      relapse after anti-CD19 immunotherapy. Clinical response and optiminzation of a standardized
      lentiviral vector and cell production protocol will be investigated. This is a phase I/II
      trial enrolling patients from multiple clinical centers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti-CD19 immunotherapy based on antibody conjugated drugs or CD19-CAR-T cells has
      demonstrated unprecedented positive response in relapsing/refractory B-cell acute
      lymphoblastic leukemia (r/r B-ALL). However, many patients still relapse and up to 30-50% of
      those relapses are characterized by the loss of CD19 surface antigen. Patients with
      CD19-negative relapse usually have a poor prognosis. The mechanisms underlying CD19-negative
      relapses are not fully understood and it is important to develop solutions to supplement
      post-CD19 immunotherapies.

      Potential markers for recurrent leukemic blasts in an emerging CD19-negative blast population
      include many known B-cell lineage antigens. To prevent further target escape and improve the
      therapeutic effects, the 4th generation CAR gene-modified T cells targeting CD22, CD10, CD20,
      CD38, or CD123 have been considered in post anti-CD19 treatment. This study aims to evaluate
      safety and efficacy of administrating one or multiple non-CD19 targeting CAR-T cells to
      patients with CD19-escaped B cell malignancies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of fourth generation anti-CD22/CD123/CD38/CD10/CD20 CAR-T cells</measure>
    <time_frame>24 weeks</time_frame>
    <description>Treatment-related adverse events are assessed by NCI CTCAE V4.0 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of fourth generation anti-CD22/CD123/CD38/CD10/CD20 CAR-T cells</measure>
    <time_frame>1 year</time_frame>
    <description>Scale of CAR copies are detected by qPCR and leukemic cell burden are assessed by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>CD19 Negative B-cell Malignancies</condition>
  <arm_group>
    <arm_group_label>4SCAR-CD22/CD123/CD38/CD10/CD20 infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20</intervention_name>
    <description>Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies</description>
    <arm_group_label>4SCAR-CD22/CD123/CD38/CD10/CD20 infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age older than 6 months.

          2. B cell malignancies relapsed after anti-CD19 immunotherapy.

          3. Malignant B cells expressing one or more of the following surface molecules:
             CD22/CD123/CD38/CD10/CD20.

          4. The KPS score over 80 points, and survival time is more than 1 month.

          5. Greater than Hgb 80 g/L.

          6. No contraindications to blood cell collection.

        Exclusion Criteria:

          1. Complications with other active diseases, and difficult to assess patient response.

          2. Bacterial, fungal, or viral infection unable to control.

          3. Living with HIV.

          4. Active HBV and HCV infection.

          5. Pregnant and nursing mothers.

          6. Under systemic steroid use within a week of the treatment.

          7. Judged difficult to cooporate for continued evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lung-Ji Chang, phD</last_name>
    <phone>+86-0755-8672-5195</phone>
    <email>c@szgimi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenzhen Children's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sixi Liu, MD</last_name>
      <phone>86-189 3869 0206</phone>
      <email>tiger647@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Lichun Xie, MD</last_name>
      <phone>86-19925192721</phone>
      <email>xielichunst@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Seventh Affilliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518107</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Wang, MD</last_name>
      <phone>86-0755-23242570</phone>
      <email>wangb68377@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shijiazhuang Zhongxi Children Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guangming Qiao, MD</last_name>
      <phone>+86-13731113069</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>4S CAR-T CD22</keyword>
  <keyword>4S CAR-T CD123</keyword>
  <keyword>4S CAR-T CD38</keyword>
  <keyword>4S CAR-T CD10</keyword>
  <keyword>4S CAR-T CD20</keyword>
  <keyword>CD19 Negative B cell leukemiaB-ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

